Featured Articles
-
How To Conduct Better Time-To-Event Analysis With Delayed Treatment Effects
9/27/2022
The issue of delayed treatment effects in immuno-oncology was demonstrated during a FDA-Industry sponsored workshop over two years ago. This demonstration made it clear that traditional log-rank tests would need to be replaced as essential assumptions of the test no longer held.
-
An Interview With Dr. Albert Kim On Simulation-Guided Design
9/27/2022
In the following interview, Cytel’s Chief Medical Officer Dr. Albert Kim speaks with Dr. Esha Senchaudhuri to discuss many aspects of simulation-guided design – its abilities, its benefits, and so much more.
-
Adaptive Designs For Early Phase Development: Are The Questions Right?
9/13/2022
In this blog, James Matcham, VP of Strategic Consulting at Cytel reviews essential new innovations in methods related to dose-escalation for single and combination studies.
-
6 Key Trials For Understanding Adaptive Designs For Clinical Trials
9/13/2022
Suppose you had to choose six clinical trials intended for registration with regulatory agencies to explain to young statisticians what the scope and promise of an adaptive or group sequential design truly is. Which trials, which methods and which strategies would you highlight?
-
Strategies For Selecting New Indications For A Platform Trial
9/13/2022
Discover how the increasing use of platform trials for the testing of a wide range of therapies raises new questions for trial design optimization and simulation.
-
Platform Trials, Master Protocols, And Challenges In Execution
9/13/2022
How can we build an efficient statistical protocol for a clinical trial, if we do not know the therapies that will be tested nor the populations on whom the testing will occur? In this blog, find out the answer to this question.
-
Sufficient Information Threshold For Effective Bayesian Applications
5/31/2022
Discover The Sufficient Information Threshold: a conceptual point that can enable asking questions about the efficiency, ethical quality, and effectiveness of a clinical study.
-
Robust Trial Design Under Treatment And Enrollment Uncertainty
5/2/2022
Learn how new technology can be harnessed to answer an array of questions about early stopping, the pacing of interim analyses, enrollment variability and cost-optimization.
-
The Urgent Need To Demonstrate Value In Real Time
5/2/2022
Systematic literature reviews (SLRs) are essential for proving product value, yet very often, the speed of scientific discovery outpaces the ability of researchers to integrate new insights into existing SLRs. Discover a new approach that ensures the most recent science is quickly incorporated into industry research programs.
-
Reinventing Clinical Trial Design: Digital Development
4/29/2022
Clinical development professionals are faced with many questions to answer and problems to solve during the product development expedition. What clinical trial design will provide the right answers at the right time? How can it be accomplished quickly and economically?